Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Pierre-Yves Loriers who wrote (638)	9/11/1998 9:03:00 AM
From: Pierre-Yves Loriers	Read Replies (2) \| Respond to of 900

The Liposome Company Receives Approval To Market ABELCET(R) In Australia; ABELCET(R) is Now Approved for Sale in 20 Countries PRINCETON, N.J., Sept. 11 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO - news) has received approval from the Therapeutic Goods Administration in Australia to market ABELCET(R) (Amphotericin B Lipid Complex Injection) for the first-line treatment of invasive fungal disease caused by organisms susceptible to amphotericin B, such as Candida, Aspergillus and Cryptococcus. Australia is the 20th country to approve ABELCET(R) and marketing applications have also been filed and are being reviewed in a number of other countries. ABELCET(R) is a proprietary lipid-based formulation of amphotericin B developed and manufactured by The Liposome Company to treat life-threatening, systemic fungal infections. These infections are especially prevalent in patients with suppressed immune systems, most often resulting from therapies for cancer or bone marrow transplants. In the United States, ABELCET(R) is the largest selling lipid-based formulation of amphotericin B. ''This approval represents a significant opportunity for the Company,'' commented Charles A. Baker, Chairman and Chief Executive Officer of The Liposome Company. ''We are pleased to add Australia to the growing list of International markets in which ABELCET(R) has been approved for marketing.'' The Liposome Company is a biopharmaceutical company developing, manufacturing and marketing therapeutic products to treat cancer and related diseases. ABELCET(R) (Amphotericin B Lipid Complex Injection) is marketed in the United States for the treatment of severe, systemic fungal infections in patients who are refractory to or intolerant of conventional therapy. Preparations are underway to file a New Drug Application before the end of this year in the U.S. for the Company's second drug, EVACET(TM) (formerly TLC D-99) liposomal doxorubicin, to treat metastatic breast cancer. The Company's product pipeline includes TLC ELL-12 , liposomal ether lipid, which is in development to treat various cancers. The company expects to file an Investigational New Drug application (IND) for TLC ELL-12 to commence human clinical studies in the latter portion of this year. Except for historical information, this press release contains forward- looking statements that involve risks and uncertainties, including but not limited to statements regarding the sales growth prospects for ABELCET(R), the filing of an NDA for EVACET(TM), the filing of an IND for TLC ELL-12 and the ability of EVACET(TM), TLC ELL-12 or any other product to be developed successfully or to gain marketing approval. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including the risk factors identified in the Registration Statement on Form S-3 dated October 29, 1997 and in the Company's subsequent SEC filings. SOURCE: The Liposome Company, Inc.